Pseudoporphyria is a photo-induced cutaneous bullous disease characterized by distinct clinical, histologic, and most recently, immunofluorescent features. By definition, results of porphyrin studies are normal in this disease. We describe here a woman with naproxeninduced pseudoporphyria, and we review previously reported cases of pseudoporphyria. The increasing frequency of pseudoporphyria is a result of the current popularity of nonsteroidal antiinflammatory drugs. Physicians need to be aware of this reversible skin disorder. Pseudoporphyria must be considered and an appropriate evaluation must be done when an individual who is taking nonsteroidal antiinflammatory drugs develops bullae and increased fragility of exposed skin.
Porphyria cutanea tarda (PCT) is a blistering disorder caused by a deficiency of uroporphyrinogen decarboxylase, an enzyme in heme biosynthesis. Porphyrins accumulate in plasma and are excreted in the urine in great excess. Exposure to sunlight results in photosensitive lesions. PCT can be inherited or acquired. Treatment alternatives include phlebotomy and antimalarial agents ( 1 4 ) .
Pseudoporphyria is a condition which has not been described until relatively recently. It exhibits PCT-like skin changes as well as similar histologic and immunofluorescence findings.